乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Psychiatry >

Schizophrenia

News, opinions and meeting coverage in psychiatry.

<乌鸦传媒>FDA Warns of Skin Reaction With Olanzapine

Zyprexa and Symbyax among products to get warning label

<乌鸦传媒>FDA Warning: Abilify Tied to Impulse Control Problems

In rare cases, may prompt "uncontrollable urges"

<乌鸦传媒>New Drug Eases Tardive Dyskinesia in Pivotal Trial

Tremors related to treatment for schizophrenia quieted by VMAT2 inhibitor

<乌鸦传媒>Zyprexa: Also a Pain Med?

Meta-analysis suggests analgesic effect for antipsychotic drug

<乌鸦传媒>Depot Drug Keeps Schizophrenics Out of Jail

NEW YORK CITY -- Schizophrenia patients who had recently been released from jail were less likely to be rearrested or otherwise fail treatment when they took a depot antipsychotic drug in a randomized trial.

<乌鸦传媒>APA Meeting Highlights Mental Health Biology

NEW YORK CITY -- The biological basis for normal and abnormal mental function is emerging as a dominant theme in psychiatry research, and the American Psychiatric Association annual meeting that starts here Saturday won't be an exception.

<乌鸦传媒>APA Leaders Defend New Diagnostic Guide

SAN FRANCISCO -- The fifth edition of the "psychiatrist's bible" was officially released here in all its 947-page glory, with its developers offering a spirited rebuttal to their critics.

<乌鸦传媒>DSM-5: What's In, What's Out

PHILADELPHIA -- Reports here provided what may be the last public update on DSM-5, the next edition of American psychiatry's diagnostic guide, before it is formally released in May 2013.

<乌鸦传媒>Most DSM-5 Revisions Pass Field Trials

PHILADELPHIA -- Field trials of proposed new diagnostic criteria for many mental disorders showed that, for the most part, they were at least adequately reliable.

<乌鸦传媒>Tardive Drug Effect Is Often Permanent

NEW ORLEANS -- Only about one patient in eight who develops tardive syndromes as a result of an antipsychotic or other drug therapy ever fully recovers, a researcher said here.

<乌鸦传媒>FDA Panel Split Over Inhaled Antipsychotic

WASHINGTON -- An FDA advisory panel punted on the question of approval for an inhaled version of the antipsychotic drug loxapine (Adasuve) to treat agitation in bipolar and schizophrenic patients, despite the risk for respiratory side effects.

<乌鸦传媒>Side Effects of Loxapine Aerosol Raise FDA Concerns

WASHINGTON -- Although staccato loxapine (Adasuve) appears to be effective in calming schizophrenic and bipolar patients, concerns remain about the drug's pulmonary side effects, according to a review by FDA staff members.

<乌鸦传媒>Early Sexual Abuse Linked to Later Psychosis

Children who are sexually abused, particularly if the abuse involves penetration, are at risk for later developing a psychotic disorder, an Australian case-control study found.

<乌鸦传媒> FDA Panel Recommends Limited Use of Investigational Antipsychotic

SILVER SPRING, Md. -- An FDA advisory panel voted to recommend FDA approval for sertindole (Serdolect) to treat schizophrenia, but only for a subgroup of patients that the agency would have to define.

<乌鸦传媒>Neurochemical May Underlie Lack of Motivation in Psychosis

CAMBRIDGE, England -- The lack of motivation characteristic of schizophrenia and other psychoses may not be a result of long-term treatment or institutionalization, researchers here suggested.

<乌鸦传媒>FDA Warns of Excess Mortality to Elderly With Antipsychotics

WASHINGTON-The FDA has issued a public health advisory on the entire class of atypical antipsychotic drugs, pointing to an apparent excess of mortality for older patients with dementia, particularly when the agents are used off-label to treat behavioral disorders.